<DOC>
	<DOC>NCT02448784</DOC>
	<brief_summary>To investigate long term safety (especially about Parkinsonism) and efficacy of donepezil hydrochloride in clinical practice as well as its proper use information in participants with DLB.</brief_summary>
	<brief_title>Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1. Naive participants diagnosed as DLB 1. Participants with a history of donepezil hydrochloride product administration in the past 2. Participants who have already been registered in this surveillance 3. Participants with a history of hypersensitivity to any ingredients of donepezil hydrochloride or piperidine derivatives</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Donepezil Hydrochloride</keyword>
	<keyword>ARICEPT</keyword>
	<keyword>Dementia</keyword>
	<keyword>Lewy bodies</keyword>
	<keyword>Dementia with Lewy bodies</keyword>
	<keyword>Post-marketing surveillance</keyword>
</DOC>